鲍氏不动杆菌121株临床分布和耐药分析

目的 了解鲍氏不动杆菌感染的临床分布及其耐药特点.方法 收集2006年1月至2007年12月从临床感染标本分离的121株鲍氏不动杆菌,了解其临床分布并做药物敏感试验,比较其耐药率.结果 121株鲍氏不动杆菌临床分布以呼吸科和ICU最多(63株,占52.07%),且多见于老年患者(67株,占55.37%);对第三代头孢菌素及环丙沙星的耐药率均>50.0%;对帕尼培南/倍他米隆、亚胺培南/西司他丁、头孢哌酮/舒巴坦的耐药性较低,分别为3.31%、6.61%、9.92%.结论 碳青霉烯类及头孢哌酮/舒巴坦对鲍氏不动杆菌感染仍有较强的活性;要减少多重耐药菌株的产生,应注意合理使用抗菌药物.

Clinical distribution and antimicrobial resistance of acinetobacter baumannii infection

Objective To observe the clinical distribution and antimicrobial resistance of Acinetobacter baumannii(A. banmannii) infection. Methods One hundred and twenty-one strains of A. banmannii from January 2006 to December 2007 were collected and drug sensitivity tests were performed. Results Sixty-three strains (52.07%) of A. baumannii were from respiratory unit and intensive care unit. Sixty-seven strains(55.37%) were from old patients. The resistant rates to the third generation cephalosperin and ciprofloxacin were beth more than 50.0% ; Drug resistance rate of A. baumannii to panipenem/betamipron, imipenem/cilastatin and cefoperazone-sul-bactam was 3.31%, 8.26%, and 13.23% respectively. Conclusion Carbapenem and cofoperazone/sulhactam still have a strong antimierobial activity against A. banmannii. Antimicrobial agents should be used rationally to decrease multiple antibiotic resistant strains.